Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-08-19), Oramed Pharmaceuticals's 10-Year Sortino Ratio is 0.47.
Oramed Pharmaceuticals (NAS:ORMP) 10-Year Sortino Ratio Explanation
The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Oramed Pharmaceuticals 10-Year Sortino Ratio Related Terms
ORMP vs CAMP, PYXS, ALEC: 10-Year Sortino Ratio Comparison
For the Biotechnology subindustry, Oramed Pharmaceuticals's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oramed Pharmaceuticals 10-Year Sortino Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's 10-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's 10-Year Sortino Ratio falls into.
Oramed Pharmaceuticals 10-Year Sortino Ratio Calculation
The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Oramed Pharmaceuticals (ORMP) has a 10-Year Sortino Ratio of 0.47 as of Aug. 19, 2026. 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. View historical data for Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' 10-Year Sortino Ratio too high?
Oramed Pharmaceuticals' current 10-Year Sortino Ratio is 0.47. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' 10-Year Sortino Ratio compare to CAMP and PYXS?
Oramed Pharmaceuticals' 10-Year Sortino Ratio of 0.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Sortino Ratio for a Biotechnology company?
A good 10-Year Sortino Ratio depends on the Biotechnology industry context. However, 10-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Sortino Ratio mean?
A high 10-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. View historical data for Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current 10-Year Sortino Ratio is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (ORMP) has a current 10-Year Sortino Ratio of 0.47. The current 10-Year Sortino Ratio is 0.47. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Sortino Ratio calculated?
10-Year Sortino Ratio is calculated from a company's financial statements. For Oramed Pharmaceuticals (ORMP), the current 10-Year Sortino Ratio is 0.47 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score
Get the complete analysis for ORMP
10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORMP has been successfully added to your 
